^
Association details:
| Biomarker: | NOTCH1 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB
Published date:
06/12/2020
Excerpt:
Patients with NOTCH1 mutations (n = 3) had higher ORR with zanubrutinib monotherapy (100% vs 36.6%; P = 0.03)....Zanubrutinib alone or in combination with an anti-CD20 antibody showed activity in the overall non-GCB DLBCL population.
